Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.69 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.67 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736552 | 0.86 | PDE10A (0.64) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL6088376 | 0.84 | CYSLTR1 (0.72) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8098339 | 0.83 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL10512475 | 0.83 | PDE10A (0.77) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL10547998 | 0.82 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL10513942 | 0.82 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL10690028 | 0.82 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10ATP53 | |
| Hydrogen Sulfide SCHEMBL9818428 | 0.82 | CYSLTR1 (0.71) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL9047808 | 0.82 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL10510977 | 0.82 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1016670-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| EP-1173193-A4 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | UNIV PRINCETON (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1173193-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | The Trustees of Princeton University (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000059528-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | CYSLTR1 2294/4885CYSLTR2 2589/4885GPBAR1 2339/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | CYSLTR1 2866/4885CYSLTR2 3183/4885GPBAR1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.